MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Kodu・Aktsiate loetelu・Avita Therapeutics Inc

Avita Therapeutics Inc

Suletud

4.4 6.28

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.36

Max

4.43

Põhinäitajad
By Trading Economics
Sissetulek	-3.3M -13M
Müük	-1.4M 17M
Kasumimarginaal	-77.289
Töötajad	260
EBITDA	-3.2M -11M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+1.35% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-2.1M 119M
Eelmine avamishind	-1.88
Eelmine sulgemishind	4.4

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

8.83 / 9.77 Toetus ja vastupanu

Avita Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. jaan 2026, 18:41 UTC

Tulu

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

24. jaan 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. jaan 2026, 09:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

24. jaan 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. jaan 2026, 09:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

24. jaan 2026, 06:18 UTC

Omandamised, ülevõtmised, äriostud

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23. jaan 2026, 22:30 UTC

Market Talk

Global Equities Roundup: Market Talk

23. jaan 2026, 22:30 UTC

Market Talk

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23. jaan 2026, 22:03 UTC

Tulu

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23. jaan 2026, 21:52 UTC

Tulu

Omandamised, ülevõtmised, äriostud

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

23. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

23. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23. jaan 2026, 21:39 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23. jaan 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23. jaan 2026, 21:12 UTC

Tulu

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23. jaan 2026, 20:31 UTC

Tulu

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23. jaan 2026, 20:12 UTC

Market Talk

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23. jaan 2026, 20:07 UTC

Market Talk

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23. jaan 2026, 19:36 UTC

Market Talk

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23. jaan 2026, 19:30 UTC

Market Talk

Tulu

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23. jaan 2026, 19:18 UTC

Market Talk

Gold and Silver Step Up to More Records -- Market Talk

23. jaan 2026, 19:15 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23. jaan 2026, 18:53 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23. jaan 2026, 18:21 UTC

Tulu

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23. jaan 2026, 18:19 UTC

Market Talk

Intel Seen as Increasingly Confident on Demand -- Market Talk

23. jaan 2026, 17:59 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23. jaan 2026, 17:57 UTC

Market Talk

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23. jaan 2026, 17:57 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Avita Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

1.35% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD 1.35%

Kõrge 5.5 USD

Madal 3.5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Avita Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Avita Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

8.83 / 9.77Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.